Advanced drug discovery tools are now being provided to Korean researchers using domestically developed technology.
In a quiet but consequential move, South Korea has opened a public gateway into one of science's most resource-intensive frontiers: the search for new medicines. The Korea Research Institute of Chemical Technology has launched a platform that allows researchers across the country to screen tens of millions of drug compounds simultaneously, using DNA as a molecular barcode system — technology that until now lived behind corporate walls and expensive foreign contracts. It is a story about who gets to look for cures, and what happens when a nation decides that question deserves a different answer.
- Korea's drug discovery researchers have long depended on costly overseas services, risking both budget strain and the quiet leakage of proprietary scientific data across borders.
- The DEL CoreBank Platform compresses what once took two months and enormous resources into weeks — millions of compounds screened in a single experiment rather than tested one painstaking well at a time.
- Major pharmaceutical companies, universities, and cancer research centers have already moved to adopt the platform, signaling that pent-up demand for accessible domestic infrastructure was real and immediate.
- A 50% government subsidy running through 2027 lowers the barrier further, while AI-powered analysis filters millions of results down to the 50 most promising drug candidates for each researcher.
- The platform is now open to any researcher with a target protein and a research question — a structural shift from scarcity to access in one of medicine's most critical early stages.
South Korea has unlocked a capability that was previously available only to well-funded corporations or researchers willing to pay for expensive international services. The Korea Research Institute of Chemical Technology, led by President Seok-Min Shin, has launched the DEL CoreBank Platform — a public service built around DNA-Encoded Library technology, which attaches unique DNA sequences to chemical compounds like barcodes on inventory items.
Rather than testing compounds one by one in separate laboratory wells — a conventional process that can take two months to screen a million candidates — DEL mixes millions of compounds together in a single solution, exposes them to disease-related target proteins, and uses genetic sequencing to identify which ones bound successfully. The DNA barcodes serve as a precise record of what worked. Building blocks are chemically linked across repeated cycles until a library of a million distinct compounds emerges from a handful of ingredients. Artificial intelligence then sorts genuine binding signals from noise, ultimately delivering the top 50 drug candidates to the researcher.
The significance for Korea is both practical and strategic. Overseas DEL services have carried high costs and raised concerns about proprietary data crossing borders. Now domestic institutions — including Daewoong Pharmaceutical, the National Cancer Center, Ewha Womans University, and GIST — are already working with the platform locally. Through 2027, the Ministry of Science and ICT and the National Research Foundation of Korea are subsidizing access at 50 percent off normal fees.
Dr. Jung-Nyoung Heo, who directs the DEL Research Center, described the goal plainly: reduce Korea's dependence on foreign technology and shorten the path from initial compound discovery to actual drug development. The platform targets small-molecule candidates for cancer, immune diseases, and infectious diseases, and is open to any researcher with a promising target protein. It marks a meaningful redistribution of who holds the keys to early-stage drug discovery.
South Korea has just opened a door that was previously locked behind expensive overseas contracts and proprietary corporate walls. The Korea Research Institute of Chemical Technology, under President Seok-Min Shin, has launched the DEL CoreBank Platform—a public service that lets researchers screen tens of millions of drug compounds in a single experiment, something that until now required either a company's own specialized equipment or a trip to an international service provider with a hefty bill attached.
The technology at the heart of this platform is deceptively elegant. DNA-Encoded Library, or DEL, works by attaching unique DNA sequences to chemical compounds like barcodes on inventory. Instead of testing compounds one by one in separate laboratory wells—the conventional method that can take two months to screen a million candidates—DEL mixes millions of compounds together in a single solution. Researchers expose this mixture to disease-related target proteins, then use genetic sequencing to identify which compounds stuck around. The DNA barcodes act as a record of what worked. A conventional high-throughput screening approach demands enormous time and protein samples; DEL compresses the same work into weeks.
The process itself is a choreography of chemistry and computation. Building blocks and their corresponding DNA tags go into 100 wells, get chemically linked, then the entire mixture gets redistributed into another 100 wells where new structures and barcodes attach. Repeat this cycle three times with different building block sets, and you've generated a library of a million distinct compounds from a handful of ingredients. When the screening is done and the DNA sequences are read, artificial intelligence trained on massive experimental datasets helps sort signal from noise—identifying which compounds are genuinely binding to the target protein versus which are false positives or artifacts of the process. The platform then selects the top 50 candidates most likely to become drugs and delivers them to the researcher.
What makes this moment significant for Korea is access and cost. Overseas DEL services have been expensive, and there's always been concern about proprietary information leaking across borders. Now domestic pharmaceutical companies, universities, and research institutes can use the platform locally. Daewoong Pharmaceutical, iLAB Inc., the National Cancer Center, Ewha Womans University, and GIST have already begun working with it. Through 2027, the government is subsidizing the service at 50 percent off the normal fee, funded by the Ministry of Science and ICT and the National Research Foundation of Korea.
Dr. Jung-Nyoung Heo, who directs the DEL Research Center, framed the initiative plainly: the goal is to reduce Korea's dependence on foreign DEL technology and accelerate the journey from initial hit discovery through to actual drug development. KRICT's president added that it matters because advanced drug discovery tools are now being provided to Korean researchers using domestically developed technology. Researchers interested in using the platform can apply through the Korea Chemical Bank website; approval depends on factors like whether their target proteins overlap with existing projects.
The platform is positioned to support discovery of small-molecule drug candidates for cancer, immune diseases, and infectious diseases. It represents a shift in how drug discovery infrastructure gets distributed—moving from a model where only well-funded companies or overseas contractors held the keys, to one where a public platform opens the work to anyone with a promising target protein and a research question.
Notable Quotes
We will help reduce Korea's dependence on overseas DEL technologies and support efficient domestic drug discovery processes from initial hit discovery to follow-up validation.— Dr. Jung-Nyoung Heo, Director of the DEL Research Center
It is meaningful that advanced drug discovery services are now being provided to Korean researchers through a DEL CoreBank platform established with domestic technologies.— KRICT President Seok-Min Shin
The Hearth Conversation Another angle on the story
Why does it matter that this is public, rather than just another company offering the service?
Because until now, if you were a researcher at a Korean university or a smaller biotech firm, you either had to pay a foreign company a lot of money or you couldn't do this kind of screening at all. Making it public with government subsidy means the barrier to entry drops dramatically. You're democratizing access to a tool that was previously gatekept.
The DNA barcode system sounds clever, but what actually goes wrong if you just mix everything together like that?
You get noise. Compounds might stick to impurities instead of your real target. Certain DNA sequences might amplify better during the sequencing step just because of their chemistry, not because the compound they're attached to actually works. That's where the AI comes in—it's trained to recognize which binding signals are real and which are artifacts.
So the AI is doing the hard interpretive work at the end?
Exactly. The screening itself is mechanical—you mix, expose, sequence. But turning that raw data into a ranked list of actual drug candidates? That requires pattern recognition across millions of data points. The AI learned what success looks like from previous experiments.
Why would Korea specifically need its own platform? Couldn't they just keep using overseas services?
Cost and control. Every time you send your research to another country, you're paying a premium and you're exposing your intellectual property. If you're a company working on a novel cancer target, you might not want that information traveling. Having a domestic platform means you keep the work and the data at home.
What happens after the platform identifies the top 50 compounds?
That's where the real drug development begins. The platform can help you resynthesis those compounds in pure form without the DNA tags, then validate them against your specific target protein. You've gone from millions of possibilities to 50 promising leads in weeks instead of months. That's a massive acceleration.
Is there a risk that this becomes a bottleneck if too many researchers want to use it?
Possibly. But the government is funding it through 2027 with the expectation that it will grow. The real test is whether the infrastructure can scale and whether the AI models stay accurate as they process more diverse targets.